Fluciclatide
Monoclonal Gammopathy Of Uncertain Significance
Explore 4 assets in Monoclonal Gammopathy Of Uncertain Significance →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Monoclonal Gammopathy Of Uncertain Significance
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluciclatide (this asset) | National Cancer Institute (NCI) | P2 | CC · 45 |
| Celecoxib | National Cancer Institute (NCI) | P2 | B |
| Linvoseltamab | Regeneron Pharmaceuticals | P2 | CCC |
| Metformin | Dana-Farber Cancer Institute | P2 | CCC |
| Isatuximab | Assistance Publique - Hôpitaux de Paris | P2 | CCC |
| Tetanus-Cmv Fusion Peptide Vaccine | City of Hope Medical Center | P1 | CC |
| Imatinib | National Cancer Institute (NCI) | P1 | CC |
| Siltuximab | Janssen Research & Development, LLC | P1 | CC |
| Ibrutinib | Jennifer Woyach | P1 | CC |
+5 more in the Monoclonal Gammopathy Of Uncertain Significance cohort
Other indications for Fluciclatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Cancer | — | P2 | CCC · 50 |
| Malignant Glioma | — | P2 | CCC · 50 |
| Lung Cancer | — | P2 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluciclatide in Monoclonal Gammopathy Of Uncertain Significance. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluciclatide-monoclonal-gammopathy-of-uncertain-significance
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →